- Companies
- Ansa Biotechnologies
Ansa Biotechnologies Funding, Investors & Competitors
Ansa Biotechnologies has raised $127M across 5 funding rounds, most recently a $45M Series B in October 2025.
Last Ansa Biotechnologies funding round
$45M
Series B · Oct 2025
Cumulative funding Ansa Biotechnologies raised
$127M
across 5 funding rounds
Key investors in Ansa Biotechnologies
Horizons Ventures
Mubadala
Humboldt Fund
Y Combinator
Northpond Ventures
Fifty Years
Fall Line Capital
Altitude Life Science Ventures
About Ansa Biotechnologies
Ansa Biotechnologies is a Berkeley-based developer of enzymatic DNA synthesis technology for biological research. Founded in 2019 by UC Berkeley alumni, the company produces longer, higher-fidelity oligonucleotides than phosphoramidite methods, enabling complex gene assembly for therapeutics and synthetic biology. Ansa's platform uses transferases for scalable synthesis up to 2,000 bases, integrated with automation for high-throughput gene libraries. Backed by ARCH Venture Partners, it serves academic labs and biotech firms in California.
Founded
2018
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales
Ansa Biotechnologies Funding History
Ansa Biotechnologies has raised a total of $127M across 5 funding rounds.
Ansa Biotechnologies' first fundraising round was a $1M pre-seed round in December 2018. The most recent completed round was a $45M Series B in October 2025.
Ansa Biotechnologies funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Oct 2025 | Series B | Cerberus Ventures (lead); Black Opal Ventures; Fall Line Capital; Altitude Life Science Ventures; Blue Water Life Science Advisors; Alternative Investment Management | $45M | Ansa Biotechnologies, Inc. is a California-based synthetic DNA company offering enzymatic DNA synthesis services, specializing in complex sequences like clonal DNA and linear double-stranded DNA fragments. It guarantees on-time delivery, such as 50 kb of clonal DNA in 24 days or less, positioning itself as a reliable alternative to traditional chemistry-based methods that take months. The company launched commercial services in May 2025 and emphasizes customer innovation in medicine and genome writing. Ansa closed an oversubscribed Series B financing round on approximately October 1, 2025, raising $45.2 million with commitments for an additional $9.2 million, totaling $54.4 million. Cerberus Ventures led the round, with participation from Blue Water Life Science Advisors, Altitude Life Science Ventures, and other existing investors. New investors included Fall Line Capital, AIM13 (Alternative Investment Management), and Black Opal Ventures. Chenny Zhang from Cerberus Ventures and Yanniv Dorone from Fall Line Capital joined the board. Proceeds will expand U.S.-based manufacturing capacity, enhance customer experience, advance strategic relationships, and drive technological innovation for novel applications. CEO Jason Gammack noted the first year of commercialization validated their reliability focus amid a tough fundraising environment competing with AI investments. The company previously raised $68 million in Series A in April 2022 and plans potential Series C and expansion to affordable states like Nevada, with current ample runway. Ansa aims to synthesize every customer sequence, currently handling more than competitors. |
| Apr 2022 | Series A | Northpond Ventures (lead) | $68M | Ansa Biotechnologies is a biotechnology company developing enzymatic DNA synthesis technology to address bottlenecks in producing long, complex DNA sequences more accurately and efficiently than chemical synthesis methods. The company closed an oversubscribed $68 million Series A financing round on April 11, 2022, led by Northpond Ventures, with participation from RA Capital, Blue Water Life Science Advisors, Altitude Life Science Ventures, Fiscus Ventures, PEAK6 Strategic Capital, Carbon Silicon Ventures, Codon Capital, and existing investors Mubadala Capital, Humboldt Fund, Fifty Years, and Horizons Ventures. This brought total funding to $82 million from private financings at that point. Proceeds from the Series A were intended to expand the interdisciplinary team, build synthesizers, scale reagent production, and launch commercial services for high-quality enzymatic DNA synthesis. Northpond Ventures highlighted Ansa's advanced technology in speed, length, and accuracy as poised to set a new industry standard. CEO Daniel Lin-Arlow emphasized rapid commercialization efforts. Subsequent developments include a Series B round in 2025 raising $54.4 million ($45.2 million closed plus $9.2 million commitments) led by Cerberus Ventures, supporting U.S. manufacturing expansion, customer guarantees like on-time delivery, and competitive pricing for low-complexity DNA. Later valuations reached $266 million as of October 2025, with total funding at $129.2 million. |
| Oct 2021 | Series A | Horizons Ventures (lead); Humboldt Fund (lead); Mubadala | $5M | - |
| Jun 2020 | Seed | Horizons Ventures (lead); Y Combinator; Humboldt Fund; Mubadala | $8M | - |
| Dec 2018 | Pre-seed | Fifty Years (lead) | $1M | - |
Who has invested in Ansa Biotechnologies?
12 investors have backed Ansa Biotechnologies across its funding rounds, including Horizons Ventures, Mubadala, Humboldt Fund, Y Combinator, Northpond Ventures and Fifty Years.
Lead investors include Cerberus Ventures, Northpond Ventures, Horizons Ventures, Humboldt Fund and Fifty Years.
Ansa Biotechnologies Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 2 | Lead | Jun 2020 | ||
| 2 | Lead | Jun 2020 | ||
| 2 | Participant | Jun 2020 | ||
| 1 | Lead | Apr 2022 | ||
| 1 | Lead | Oct 2025 | ||
| 1 | Participant | Jun 2020 | ||
| 1 | Participant | Oct 2025 | ||
| 1 | Lead | Dec 2018 | ||
| 1 | Participant | Oct 2025 | ||
| 1 | Participant | Oct 2025 | ||
This data is available for Pro users. Sign up to see all 12 Ansa Biotechnologies investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAnsa Biotechnologies Competitors
Ansa Biotechnologies competitors include listed companies like SAP and Merck KGaA, and private ones like Astromech, Intrepid Labs, Chai Discovery and Anew Labs.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | - | - | $3.8B | - | ||
| Private | - | - | $6.8B | - | ||
| Private | $48M | - | $3.8B | - | ||
| Private | - | - | $1.5B | - | ||
| Publicly listed | $42B | $13B | $248B | 5.4x | ||
| Publicly listed | $24B | $5.3B | $66B | 3.1x |
Ansa Biotechnologies Public Comps
Ansa Biotechnologies is still privately-owned, but its public comps include CrowdStrike, SAP, Salesforce, ServiceNow, Adobe, Datadog, Moody's, Merck KGaA, Workday and Illumina.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $4.8B | ($12M) | 51.4x | 44.5x | (19816.2x) | 151.0x | |||
| $42B | $13B | 5.8x | 5.4x | 18.4x | 17.1x | |||
| $42B | $13B | 5.5x | 5.2x | 17.8x | 12.2x | |||
| $13B | $2.6B | 11.1x | 9.6x | 57.2x | 25.0x | |||
| $24B | $9.3B | 4.3x | 3.9x | 10.9x | 8.2x | |||
| $3.4B | ($588K) | 23.6x | 19.4x | (137813.0x) | 77.6x | |||
| $7.7B | $3.8B | 11.2x | 10.6x | 22.5x | 20.1x | |||
| $24B | $5.3B | 3.1x | 3.1x | 14.3x | 10.7x | |||
This data is available for Pro users. Sign up to see all Ansa Biotechnologies competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Ansa Biotechnologies
| When was Ansa Biotechnologies founded? | Ansa Biotechnologies was founded in 2018. |
| Where is Ansa Biotechnologies headquartered? | Ansa Biotechnologies is headquartered in San Francisco, CA, United States. |
| Is Ansa Biotechnologies publicly listed? | No, Ansa Biotechnologies is a private, VC-backed company. |
| How much funding has Ansa Biotechnologies raised? | Ansa Biotechnologies has raised $127M across 5 funding rounds. |
| What was Ansa Biotechnologies' last funding round? | Ansa Biotechnologies' last funding round was a $45M Series B in October 2025, led by Cerberus Ventures. |
| Who are Ansa Biotechnologies' investors? | Ansa Biotechnologies' investors include Humboldt Fund, Horizons Ventures, Mubadala, Northpond Ventures, Cerberus Ventures, Y Combinator, Black Opal Ventures, Fifty Years, Fall Line Capital, Altitude Life Science Ventures and 2 others. |
| Which companies are comparable to Ansa Biotechnologies? | Companies comparable to Ansa Biotechnologies include Astromech, Intrepid Labs, Chai Discovery, Anew Labs, SAP and Merck KGaA. |
See companies similar to Ansa Biotechnologies
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




